Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenicriviroc - Tobira Therapeutics

Drug Profile

Cenicriviroc - Tobira Therapeutics

Alternative Names: Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 17 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer Allergan; Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Novartis; Tobira Therapeutics; University of Hawaii
  • Class Amides; Antifibrotics; Antineoplastics; Antiretrovirals; Imidazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Cognition disorders; HIV-1 infections; Non-alcoholic fatty liver disease; Primary sclerosing cholangitis
  • Phase I Liver disorders
  • Preclinical Cholestasis; Diabetic nephropathies
  • No development reported Cancer; Graft-versus-host disease

Most Recent Events

  • 07 Jun 2019 Efficacy and pharmacodynamics data from the phase IIb CENTAUR trial in Non-alcoholic steatohepatitis presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)
  • 17 Dec 2017 Allergan completes a phase I trial in Liver disorders in USA (PO) (NCT03376841)
  • 10 Nov 2017 Tobira Therapeutics completes the phase IIb CENTAUR trial for Non-alcoholic steatohepatitis in Australia, Belgium, France, Germany, Hong Kong, Italy, Moldova, Poland, Spain, USA and United Kingdom (PO) (NCT02217475)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top